Results 201 to 210 of about 260,030 (390)

Comparative efficacy and safety of anakinra and canakinumab in patients with VEXAS syndrome – an international multicenter study

Arthritis &Rheumatology, Accepted Article.
Objectives The aim of this study was to compare differences in clinical response, drug survival, and adverse event rates between anakinra and canakinumab in VEXAS syndrome. Methods This multicenter international study includes VEXAS patients from France, Israel, and Italy treated with IL1 inhibition (IL1i).
Tali Eviatar, Dafne Capelusnik, Corrado Campochiaro, Valentin Lacombe, Vincent Jachiet, Michael Zisapel, Iftach Sagy, Oshrat E. Tayer‐Shifman, David Ozeri, Shaye Kivity, Alessandro Tomelleri, Benjamin Terrier, Hagit Peleg, Thibault Comont, Karim Sacre, Pascal Woaye‐Hune, Laurent Arnaud, Estibaliz Lazaro, Vincent Grobost, Francois Lifermann, Maxime Samson, Samuel Ardois, Alice Garnier, Alexandre Maria, Alain Cantagrel, Aurore Meyer, Jean‐David Bouaziz, Mael Heiblig, Lorenzo Dagna, Elisa Diral, Olivier Kosmider, Ori Elkayam, Jérôme Hadjadj, Sophie Georgin‐Lavialle, Olivier Fain, Arsene Mekinian   +35 more
wiley   +1 more source

Photokopolimerisasi monomer akrilat degan kulit kras sapi

, 1997
Dwi Wahini Nurhajati, Agustin Suraswati, Kadarijah Kadarijah, Made Sumarti   +3 more
openalex   +2 more sources

Krš ili kras? Krš!

Geografski horizont, 2008
U radu se iznosi opravdanost termina krš i razlozi zbog kojih taj termin ima prednost pred terminom kras.
openaire   +3 more sources

Polskie rozwiązania w zakresie rezerw obowiązkowych banków

Seminare, 2004
Ireneusz Kraś
doaj   +1 more source

Multivariate Analysis in Skull Osteometry of the Common Tree Shrew from Both Sides of the Isthmus of Kra in Southern Thailand.

, 2000
Hideki Endo, Isao Nishiumi, Yoshihiro Hayashi, Azmin Bin Mohd Rashdi, Nivesh Nadee, Jarujin Nabhitabhata, Yoshi Kawamoto, Junpei Kimura, Takao NISHIDA, Junzo Yamada   +9 more
openalex   +2 more sources

Gene expression profiling of epidermal growth factor receptor/KRAS pathway activation in lung adenocarcinoma [PDF]

, 2007
Tatsuhiro Shibata, Satoko Hanada, Akiko Kokubu, Yoshihiro Matsuno, Hisao Asamura, Tsutomu Ohta, Michiie Sakamoto, Setsuo Hirohashi   +7 more
openalex   +1 more source

Efficacy and safety of glecirasib in solid tumors with KRAS G12C mutation: A pooled analysis of two phase I/II trials

Cancer Communications, EarlyView.
Abstract Background Glecirasib, an inhibitor of Kirsten rat sarcoma viral oncogene homolog glycine‐to‐cysteine substitution at codon 12 (KRAS G12C), has exhibited clinical activity in non‐small‐cell lung cancer (NSCLC) and colorectal cancer (CRC).
Jian Li, Ting Deng, Yanhong Gu, Antonio Calles Blanco, Zhihua Li, Chunmei Bai, Lin Wu, Jing Huang, Xingya Li, Yu Yao, Zhengbo Song, Yongsheng Li, Lian Liu, Ligang Xing, Wenming Wu, Julia Martínez‐Pérez, Ayala Hubert, Jon Zugazagoitia, Jian Zhang, Yongsheng Wang, Yanqiu Zhao, Guilan Wen, Guohao Xia, Diansheng Zhong, Xueqin Chen, Kuirong Jiang, Andrea Wang‐Gillam, Yuli Ding, Sumei Liu, Zhiyue Rao, Xinghu Liu, Lin Shen   +31 more
wiley   +1 more source

Mechanism and role of regulated cell death in tumor immunity and immunotherapy

Cancer Communications, EarlyView.
Abstract Cancer immune checkpoint inhibitors (ICIs) have brought breakthroughs, but only about one‐third of cancer patients benefit from ICIs. In recent years, targeting non‐apoptotic regulated cell death (RCD) subtypes, such as ferroptosis, necroptosis, autophagy, cuproptosis, and pyroptosis, has emerged as a novel strategy in cancer therapy due to ...
Jingwen Hu, Yan Li, Bingjie Lian, Yitao Mao, Luqing Zhao   +4 more
wiley   +1 more source

Krüppel-Like Factor 5 Mediates Cellular Transformation During Oncogenic KRAS-Induced Intestinal Tumorigenesis [PDF]

, 2007
Mandayam O. Nandan, Beth B. McConnell, Amr M. Ghaleb, Agnieszka B. Bialkowska, Hongmiao Sheng, Jinyi Shao, Brian A. Babbin, Sylvie Robine, Vincent W. Yang   +8 more
openalex   +1 more source

CD24 is a promising immunotherapeutic target for enhancing efficacy of third‐generation EGFR‐TKIs on EGFR‐mutated lung cancer

Cancer Communications, EarlyView.
Abstract Background Third‐generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) show initial efficacy in EGFR‐mutated lung cancer, but residual disease persists. This study aimed to investigate cluster of differentiation 24 (CD24) as a translational immunotherapeutic target for enhancing third‐generation EGFR‐TKI efficacy.
Jiaqi Liang, Guoshu Bi, Xiaolong Huang, Zhijie Xu, Yiwei Huang, Yunyi Bian, Guangyao Shan, Wei Guo, Yuanliang Yan, Qihai Sui, Xiaodong Yang, Zhencong Chen, Tao Lu, Huan Zhang, Qun Wang, Wei Jiang, Cheng Zhan   +16 more
wiley   +1 more source